Glaxosmithkline
Dividend policies and expected pay-out ratios are unchanged for new GSK and new Consumer Healthcare (subject to new Consumer Healthcare board approval).
Quarterly dividends
The Board has declared a first interim dividend for 2022 of 14 pence per share (Q1 2021: 19 pence per share).
As set out at the new GSK Investor Update in June 2021, from 2022 GSK will adopt a progressive dividend policy targeting a dividend pay-out ratio equivalent to 40 to 60% over the investment cycle. The dividend policy, the total expected cash distribution, and the respective dividend pay-out ratios for new GSK and new Consumer Healthcare remain unchanged.
GSK expects to declare a 27p per share dividend payable by the current group for the first half. This comprises 22p per share for new GSK and 5p per share representing Consumer Healthcare during the first half whilst part of the group. For the second half of 2022, new GSK continues to expect to declare a 22p per share dividend. As previously communicated, new GSK would expect to declare a dividend of 45p per share for 2023.
Following separation, the dividend policy for the new Consumer Healthcare company will be the responsibility of its Board of Directors and is expected to be guided by a 30 to 50 per cent pay-out ratio. We expect a second-half dividend from the new Consumer Healthcare company equivalent to a pay-out of around 3p per share, subject to its Board's decisions on the intra-year phasing of dividend payments.
In aggregate, this would represent on the full year 2022 basis the equivalent of a Group dividend of around 52p per share. Dividends payable by Consumer Healthcare will only be receivable by shareholders who remain invested in Consumer Healthcare post-separation and at the appropriate record dates.
Payment of dividends
The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 29 June 2022. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary.
The ex-dividend date will be 19 May 2022, with a record date of 20 May 2022 and a payment date of 1 July 2022.
Wer sich die Mühe machen möchte, kann das im Q1 Bericht finden inklusive einer Zeittabelle der zukünftigen Zahlungen
https://www.ariva.de/news/...t-us-impfspezialisten-affinivax-10171232
Was haltet ihr von der Übernahme?
Optionen
| Boardmail an "Highländer49" |
Wertpapier: GSK Glaxo Smith Kline P |
https://www.gsk.com/en-gb/media/press-releases/...pany-affinivax-inc/
Optionen
| Boardmail an "Highländer49" |
Wertpapier: GSK Glaxo Smith Kline P |
https://www.wallstreet-online.de/nachricht/...off-geschaeft-angreifen
Optionen
| Boardmail an "Highländer49" |
Wertpapier: GSK Glaxo Smith Kline P |
Hallo, akzeptiere deine Meinung mit der Bemerkung, dass bei Abspaltung von Daimler Truck von Daimler AG und neu Mercedes Benz alles ohne Steuergefummel oder Gewinnversteuerung ablief.
https://www.deraktionaer.de/artikel/...n-seit-10-jahren-20251254.html
ist jemand von euch bei der comdirect und hat heute ebenfalls das Umtauschangebot erhalten? Muss man darauf irgendwie reagieren oder werden die Aktien automatisch 1:1 eingebucht?
Vielen Dank im Voraus!
GSK beginnt dann Handel ohne Consumer, so dass Kurs fallen wird.Nach Handelsschluss vom 1.Tag erfolgt Konsolidierung bei GSK und Kurs kehrt zurück zu gleichen Stand wie vor Spaltung, somit Vergleichbarkeit mit Vorperioden. D.h. die Konsolidierung wird die Gesamtzahl der ausgegebenen GSK-Aktien bei gleichzeitiger Steigerung des Individuellen Wertes verringern. Also ein komplizierter Prozess.
